Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis
Abstract Aim To assess the effect of empagliflozin on patients with comorbid heart failure (HF) and diabetes with or without baseline insulin, and to study the impact of empagliflozin on insulin requirements over time. Materials and Methods We performed a post-hoc analysis of pooled patient-level da...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2024
|
| In: |
Diabetes, obesity and metabolism
Year: 2024, Jahrgang: 26, Heft: 7, Pages: 2578-2587 |
| ISSN: | 1463-1326 |
| DOI: | 10.1111/dom.15572 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1111/dom.15572 Verlag, kostenfrei, Volltext: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15572 
|
| Verfasserangaben: | Khawaja M. Talha MBBS, Jennifer Green MD, Gerasimos Filippatos MD, Stuart Pocock PhD, Faiez Zannad MD, Martina Brueckmann MD, Elke Schueler, Anne Pernille Ofstad MD, João Pedro Ferreira MD, Stefan D. Anker MD, Javed Butler MD, Julio Rosenstock MD, Milton Packer MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1916276938 | ||
| 003 | DE-627 | ||
| 005 | 20250716230026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250204s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.15572 |2 doi | |
| 035 | |a (DE-627)1916276938 | ||
| 035 | |a (DE-599)KXP1916276938 | ||
| 035 | |a (OCoLC)1528018494 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Talha, Khawaja M. |e VerfasserIn |0 (DE-588)1355170575 |0 (DE-627)1916277241 |4 aut | |
| 245 | 1 | 0 | |a Impact of empagliflozin on insulin needs in patients with heart failure and diabetes |b An EMPEROR-Pooled analysis |c Khawaja M. Talha MBBS, Jennifer Green MD, Gerasimos Filippatos MD, Stuart Pocock PhD, Faiez Zannad MD, Martina Brueckmann MD, Elke Schueler, Anne Pernille Ofstad MD, João Pedro Ferreira MD, Stefan D. Anker MD, Javed Butler MD, Julio Rosenstock MD, Milton Packer MD |
| 264 | 1 | |c July 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 1. April 2024 | ||
| 500 | |a Gesehen am 04.02.2025 | ||
| 520 | |a Abstract Aim To assess the effect of empagliflozin on patients with comorbid heart failure (HF) and diabetes with or without baseline insulin, and to study the impact of empagliflozin on insulin requirements over time. Materials and Methods We performed a post-hoc analysis of pooled patient-level data from two cardiovascular outcomes trials of empagliflozin in HF (EMPEROR-Reduced and EMPEROR-Preserved trials). We undertook a subgroup analysis stratified by baseline insulin use, including all patients with diabetes. The studied endpoints included the primary composite endpoint of first hospitalization for HF or cardiovascular death, rate of decline of estimated glomerular filtration rate, composite renal outcome and rates of sustained insulin initiation. Results Among 4794 patients with diabetes, 1333 (658 in empagliflozin, 675 in placebo) were using insulin at baseline. The treatment effect of empagliflozin on the primary endpoint was consistent irrespective of insulin use [no insulin, hazard ratio 0.74, 95% confidence interval (CI) 0.63-0.86; using insulin, hazard ratio 0.81, 95% CI 0.66-1.00, pinteraction?=?.49], as was the effect on the rate of decline of the estimated glomerular filtration rate (pinteraction?=?.75). There was no effect of empagliflozin on the composite renal outcome in patients using or not using insulin (pinteraction?=?.30). Among patients not using insulin at baseline, those randomized to empagliflozin initiated insulin less frequently throughout the follow-up period compared with those receiving placebo (2.6% vs. 3.8%, odds ratio 0.66, 95% CI 0.50-0.88). Conclusions Empagliflozin exerts a consistent benefit on cardiovascular outcomes and renal function decline, irrespective of baseline insulin use, and reduces the need for sustained insulin initiation in patients with HF and diabetes. | ||
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a empagliflozin | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a insulin therapy | |
| 700 | 1 | |a Green, Jennifer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pocock, Stuart |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Schueler, Elke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ofstad, Anne Pernille |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferreira, João Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rosenstock, Julio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Packer, Milton |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity and metabolism |d Oxford [u.a.] : Wiley-Blackwell, 1999 |g 26(2024), 7, Seite 2578-2587 |h Online-Ressource |w (DE-627)320440982 |w (DE-600)2004918-3 |w (DE-576)091142679 |x 1463-1326 |7 nnas |a Impact of empagliflozin on insulin needs in patients with heart failure and diabetes An EMPEROR-Pooled analysis |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:7 |g pages:2578-2587 |g extent:10 |a Impact of empagliflozin on insulin needs in patients with heart failure and diabetes An EMPEROR-Pooled analysis |
| 856 | 4 | 0 | |u https://doi.org/10.1111/dom.15572 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15572 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250204 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 6 | ||
| 999 | |a KXP-PPN1916276938 |e 4660301109 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"July 2024","dateIssuedKey":"2024"}],"name":{"displayForm":["Khawaja M. Talha MBBS, Jennifer Green MD, Gerasimos Filippatos MD, Stuart Pocock PhD, Faiez Zannad MD, Martina Brueckmann MD, Elke Schueler, Anne Pernille Ofstad MD, João Pedro Ferreira MD, Stefan D. Anker MD, Javed Butler MD, Julio Rosenstock MD, Milton Packer MD"]},"relHost":[{"pubHistory":["1.1999 -"],"disp":"Impact of empagliflozin on insulin needs in patients with heart failure and diabetes An EMPEROR-Pooled analysisDiabetes, obesity and metabolism","origin":[{"dateIssuedDisp":"1999-","publisher":"Wiley-Blackwell ; Blackwell ; Blackwell Science","dateIssuedKey":"1999","publisherPlace":"Oxford [u.a.] ; Oxford [u.a.] ; Oxford"}],"recId":"320440982","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2004918-3"],"issn":["1463-1326"],"eki":["320440982"],"doi":["10.1111/(ISSN)1463-1326"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Diabetes, obesity and metabolism","title_sort":"Diabetes, obesity and metabolism"}],"note":["Gesehen am 28.10.03"],"part":{"volume":"26","pages":"2578-2587","year":"2024","text":"26(2024), 7, Seite 2578-2587","issue":"7","extent":"10"}}],"id":{"eki":["1916276938"],"doi":["10.1111/dom.15572"]},"language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"10 S."}],"recId":"1916276938","note":["Online veröffentlicht: 1. April 2024","Gesehen am 04.02.2025"],"person":[{"display":"Talha, Khawaja M.","family":"Talha","roleDisplay":"VerfasserIn","role":"aut","given":"Khawaja M."},{"role":"aut","given":"Jennifer","roleDisplay":"VerfasserIn","display":"Green, Jennifer","family":"Green"},{"family":"Filippatos","display":"Filippatos, Gerasimos","roleDisplay":"VerfasserIn","given":"Gerasimos","role":"aut"},{"family":"Pocock","display":"Pocock, Stuart","roleDisplay":"VerfasserIn","role":"aut","given":"Stuart"},{"given":"Faiez","role":"aut","roleDisplay":"VerfasserIn","display":"Zannad, Faiez","family":"Zannad"},{"role":"aut","given":"Martina","roleDisplay":"VerfasserIn","display":"Brückmann, Martina","family":"Brückmann"},{"roleDisplay":"VerfasserIn","display":"Schueler, Elke","family":"Schueler","role":"aut","given":"Elke"},{"role":"aut","given":"Anne Pernille","roleDisplay":"VerfasserIn","display":"Ofstad, Anne Pernille","family":"Ofstad"},{"given":"João Pedro","role":"aut","roleDisplay":"VerfasserIn","display":"Ferreira, João Pedro","family":"Ferreira"},{"family":"Anker","display":"Anker, Stefan D.","roleDisplay":"VerfasserIn","given":"Stefan D.","role":"aut"},{"display":"Butler, Javed","family":"Butler","roleDisplay":"VerfasserIn","role":"aut","given":"Javed"},{"display":"Rosenstock, Julio","family":"Rosenstock","roleDisplay":"VerfasserIn","role":"aut","given":"Julio"},{"role":"aut","given":"Milton","display":"Packer, Milton","family":"Packer","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Impact of empagliflozin on insulin needs in patients with heart failure and diabetes","title":"Impact of empagliflozin on insulin needs in patients with heart failure and diabetes","subtitle":"An EMPEROR-Pooled analysis"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a TALHAKHAWAIMPACTOFEM2024 | ||